IP Verse

Adjuvant Treatment Of Her2-Positive Breast Cancer

Patent No. EP3589661 (titled "Adjuvant Treatment Of Her2-Positive Breast Cancer") was filed by F Hoffmann LA Roche on Feb 28, 2018. The application was issued on Nov 1, 2023.

Patent Summary

Combination therapy for HER2-positive breast cancer that extends survival compared to trastuzumab alone. The treatment combines pertuzumab with trastuzumab and chemotherapy, administered after breast surgery. The combination provides enhanced anti-tumor activity against HER2-positive breast cancer while addressing potential resistance mechanisms.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MICHALSKI HUTTERAMNN & PARTNER PATENTANWALTE MBBAug 1, 2024-
ABEL & IMRAYJul 31, 2024-
LANYON OPPOSITIONSJul 31, 2024PINSENT MASONS
BRAND MURRAY FULLERJul 23, 2024BRAND MURRAY FULLER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3589661

F HOFFMANN LA ROCHE
Application Number
EP18712044A
Filing Date
Feb 28, 2018
Status
Granted And Under Opposition
Sep 29, 2023
Publication Date
Nov 1, 2023
External Links
Slate, Register , Google Patents